Core Viewpoint - Kangzheng Pharmaceutical (00867) has seen a stock increase of over 3%, currently trading at HKD 14.47, with a transaction volume of HKD 18.3861 million. The company announced that its subsidiary, Demy Pharmaceutical, has received approval from the National Medical Products Administration (NMPA) for the new drug application (NDA) of Ruxolitinib cream for the treatment of non-segmental vitiligo, marking it as the first and only targeted therapy for this condition in China, addressing a significant unmet clinical need [1][1][1]. Company Summary - Demy Pharmaceutical, focusing on skin health, is applying for an independent listing on the Hong Kong Stock Exchange by January 30, 2026 [1]. - The Ruxolitinib cream is a JAK1/JAK2 inhibitor developed by Incyte and is the first FDA-approved drug for repigmentation in non-segmental vitiligo [1][1]. - The company estimates that approximately 10.3 million people in China suffer from vitiligo, with 8.2 million having non-segmental vitiligo, highlighting the potential market size for the new treatment [1][1]. Industry Summary - Current treatments for vitiligo, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical shortcomings, including adverse reactions and limited efficacy with long-term use [1]. - The approval of Ruxolitinib cream is expected to fill the gap in targeted treatment for vitiligo in China, meeting a significant clinical demand [1][1].
港股异动 | 康哲药业(00867)涨超3% 机构指芦可替尼乳膏国内获批有望填补白癜风靶向治疗空白